Vaigensell Selected for Oral Presentation at EHA... "Global Academic Community’s Attention Follows ASCO"

Vaigensell, a company specializing in new drug development, announced on May 13 that the results of the phase 2 clinical trial for its NK/T-cell lymphoma treatment, 'VT-EBV-N', have been selected for an Oral Presentation at the European Hematology Association (EHA 2026) Congress.

The European Hematology Association Congress (EHA), together with the American Society of Hematology (ASH), is one of the world’s most prestigious conferences in the field of hematologic malignancies. This year, it will be held in Stockholm, Sweden, from June 11 to 14 (local time).

This selection follows the recent achievement of being chosen as the first Korean cell therapy to be included in a formal Oral Presentation session at the American Society of Clinical Oncology (ASCO 2026) later this month. With this, Vaigensell has once again demonstrated the clinical excellence of 'VT-EBV-N' on both of the world’s most authoritative academic stages in the oncology and hematology fields—the United States and Europe.

At this year’s EHA, Vaigensell will present the results of its phase 2 clinical trial targeting patients with EBV-positive extra-nodal NK/T-cell lymphoma. In this randomized, double-blind study, 'VT-EBV-N' statistically and significantly improved disease-free survival (DFS) in the treatment group, confirming meaningful outcomes in terms of prognosis improvement for patients.

NK/T-cell lymphoma is a rare hematologic cancer for which no standard treatment has been established. It is characterized by a high relapse rate and poor prognosis, resulting in a very high level of unmet medical needs. Through this study, Vaigensell has demonstrated the potential to reduce the risk of relapse and improve survival, setting new therapeutic standards for the global academic community.

Formal oral presentations are reserved for only a handful of studies among thousands of abstracts submitted, with selection based on academic significance and impact. Vaigensell plans to leverage the trust built through successive presentations at global conferences to accelerate global partnerships and achieve commercialization milestones.

Park Pyungseok, CEO of Vaigensell, stated, "Being consecutively selected for oral presentations at both ASCO and EHA is evidence that global experts are paying attention to the value of the clinical data for 'VT-EBV-N'. Based on the research competitiveness recognized on the world stage, we will do our utmost to achieve global commercialization and enhance our corporate value."